{"title":"Growth Hormone Secretagogues","description":"\u003ch2 id=\"tinymce_scroll_sign\"\u003eExploring the Best Growth Hormone Secretagogues for Optimal Results\u003c\/h2\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3\u003eWhat Are Growth Hormone Secretagogues?\u003c\/h3\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003eThe best growth hormone secretagogues are compounds that stimulate the body’s natural production of growth hormone, helping improve muscle growth, recovery, and overall vitality. These secretagogues work by signaling the pituitary gland to increase hormone release, supporting anti-aging and metabolic benefits. Unlike synthetic HGH injections, these natural boosters promote a healthier hormone balance without disruptive side effects. Choosing the right secretagogue can enhance performance and wellness by harnessing the body's own mechanisms.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3\u003eTop Natural Growth Hormone Secretagogues\u003c\/h3\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003eAmong the best growth hormone secretagogues, popular options include amino acids like arginine, glutamine, and GABA. These ingredients are known for their ability to safely elevate growth hormone levels after workouts or during sleep, enhancing muscle recovery and fat metabolism. Additionally, peptides such as ipamorelin and sermorelin have gained attention for their targeted stimulation of HGH release. These natural and synthetic secretagogues offer various approaches, allowing users to select one that fits their lifestyle and health priorities.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3\u003eBenefits and Considerations When Using Secretagogues\u003c\/h3\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003eUsing the best growth hormone secretagogues can lead to improved muscle mass, faster recovery, better sleep, and increased energy. However, it’s important to use these supplements responsibly, ideally under medical supervision, to avoid potential side effects or interactions. Individual results vary based on factors like age, diet, and exercise routine. When paired with proper nutrition and training, growth hormone secretagogues can be powerful tools in achieving fitness and health goals naturally and effectively.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e","products":[{"product_id":"bacteriostatic-water-bac-water","title":"Bacteriostatic Water (BAC Water)","description":"\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eBacteriostatic Water | BAC Water | Sterile Peptide Reconstitution Solution | Research Grade\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eComposition:\u003c\/strong\u003e Sterile water for injection + 0.9% benzyl alcohol (9 mg\/mL) \u003cstrong\u003eGrade:\u003c\/strong\u003e Research grade — sterile, pyrogen-free \u003cstrong\u003ePreservative:\u003c\/strong\u003e Benzyl alcohol 0.9% (v\/v) \u003cstrong\u003epH:\u003c\/strong\u003e 4.5–7.0 \u003cstrong\u003eAppearance:\u003c\/strong\u003e Clear, colourless solution \u003cstrong\u003ePackaging:\u003c\/strong\u003e Sealed multi-dose vials \u003cstrong\u003eStorage:\u003c\/strong\u003e Room temperature (15–25°C), away from light; refrigerate after opening\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eWhat Is Bacteriostatic Water?\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eBacteriostatic water (BAC water) is a preparation of sterile water for injection containing 0.9% benzyl alcohol (9 mg\/mL) as a preservative. The term \"bacteriostatic\" refers to the benzyl alcohol component — a broad-spectrum antimicrobial agent that inhibits bacterial growth and multiplication within the vial, without necessarily killing bacteria outright. This preservative action allows BAC water to remain safely usable across multiple withdrawals over an extended period — a critical property that distinguishes it from standard sterile water for injection, which is intended for single-use only and carries no microbial protection after the vial seal is first broken.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eBAC water is the standard reconstitution vehicle for a wide range of lyophilised research peptides, proteins, and biological compounds — including human growth hormone (HGH), GHRFs, GHRPs, and most synthetic research peptides. It is used wherever a multi-dose reconstitution protocol is required, and where peptide or protein stability across multiple draw-down events must be maintained without microbial contamination risk.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eOur bacteriostatic water is manufactured to research grade: sterile, pyrogen-free, and packaged in sealed multi-dose vials with halogenated butyl stoppers compatible with standard research syringes and needle gauges.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eWhy BAC Water Matters for Peptide Research\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eThe choice of reconstitution vehicle is one of the most practically consequential decisions in peptide research — and one that is frequently underestimated. Using an inappropriate reconstitution solution can compromise peptide stability, alter solubility, affect experimental reproducibility, and — in the case of multi-dose vials — introduce microbial contamination that invalidates results and degrades the compound.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eBacteriostatic water addresses these concerns by providing a chemically inert, pH-appropriate, sterile environment with sustained antimicrobial protection across repeated vial access events. For researchers working with lyophilised peptides that require reconstitution before use — including every compound in our research catalogue — BAC water is the most broadly appropriate and widely used reconstitution vehicle in the scientific literature.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eCompatibility with our catalogue:\u003c\/strong\u003e BAC water is the recommended reconstitution vehicle for HGH (somatotropin), tesamorelin, BPC-157, TB-500, MOTS-c, Selank, and the majority of other lyophilised research peptides. GHK-Cu is optimally reconstituted in sterile water or PBS, and 5-Amino-1MQ may require DMSO for certain protocols — but for the majority of peptide reconstitution applications, BAC water is the first-choice solution.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eComposition \u0026amp; Technical Specifications\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eWhy 0.9% benzyl alcohol?\u003c\/strong\u003e Benzyl alcohol has been used as an antimicrobial preservative in injectable preparations since the 1920s. At 0.9% concentration, it provides effective bacteriostatic activity against a broad spectrum of gram-positive and gram-negative bacteria — the most likely contaminants in a multi-access vial environment — while remaining chemically compatible with the widest range of peptides, proteins, and hormones used in research. Higher benzyl alcohol concentrations can begin to affect protein folding and stability; 0.9% represents the established standard for balancing preservation efficacy with compound compatibility.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eWhy not sterile water for injection?\u003c\/strong\u003e Standard sterile water for injection (SWFI) contains no preservative and is intended for single-use only. Once the seal is broken and the vial accessed, SWFI provides no protection against bacterial contamination from subsequent needle insertions. For researchers who routinely draw multiple aliquots from a single reconstituted vial over days or weeks — as is standard practice with peptide research compounds — SWFI is inappropriate and significantly increases the risk of microbial contamination that will degrade the compound and compromise experimental results.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eWhy not saline or PBS?\u003c\/strong\u003e Normal saline (0.9% sodium chloride) and phosphate-buffered saline (PBS) are appropriate for some peptide reconstitution applications but carry important caveats. Saline can reduce the solubility of certain peptides and proteins and provides no preservative action in multi-dose vials. PBS introduces phosphate and salt ions that can interact with some peptides and alter their behaviour in downstream assays. For most lyophilised research peptide applications, BAC water provides a cleaner, more universally compatible, and more practically convenient reconstitution vehicle.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eBAC Water and Peptide Stability\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eProper reconstitution practice is as important as purity when it comes to preserving the integrity and research utility of lyophilised peptides. The following principles apply to reconstitution with BAC water across the research peptide catalogue:\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eTechnique:\u003c\/strong\u003e Always inject BAC water slowly against the side of the vial — never directly onto the lyophilised powder, which can mechanically disrupt peptide structure. Swirl gently until dissolved; do not shake or vortex.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eTemperature:\u003c\/strong\u003e Allow the lyophilised vial to reach room temperature before reconstitution. Cold powder reconstituted with room-temperature water can produce localised concentration gradients that slow dissolution.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eStorage after reconstitution:\u003c\/strong\u003e Reconstituted peptides in BAC water should be stored at 2–8°C (refrigerated). The benzyl alcohol preservative protects against microbial growth but does not prevent peptide degradation from heat or light exposure. Reconstituted solutions should be used within the timeframes recommended for each specific compound — typically 28 days for HGH and tesamorelin, and up to 30 days for shorter synthetic peptides, though this varies by compound.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eFreeze-thaw:\u003c\/strong\u003e Reconstituted peptide solutions in BAC water should not be re-frozen unless the specific compound's data sheet indicates this is acceptable. For long-term storage, lyophilise in advance of reconstitution or aliquot before the first freeze-thaw cycle.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eProduct Specifications\u003c\/h3\u003e\n\u003cdiv class=\"overflow-x-auto w-full px-2 mb-6\"\u003e\n\u003ctable class=\"min-w-full border-collapse text-sm leading-[1.7] whitespace-normal\"\u003e\n\u003cthead class=\"text-left\"\u003e\n\u003ctr\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eSpecification\u003c\/th\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eDetail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eComposition\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eWater for injection + 0.9% benzyl alcohol (9 mg\/mL)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eGrade\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eResearch grade — sterile, pyrogen-free\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePreservative\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eBenzyl alcohol 0.9% (v\/v)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003epH\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e4.5–7.0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eOsmolality\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e~9 mOsm\/kg (hypotonic)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eAppearance\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eClear, colourless solution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePackaging\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSealed multi-dose vials with halogenated butyl stopper\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eStorage\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eRoom temperature (15–25°C), away from light; refrigerate after opening\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eShelf Life\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eAs labelled on vial; discard 28 days after first opening\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eQuality \u0026amp; Purity Assurance\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eOur bacteriostatic water is manufactured to research-grade standards:\u003c\/p\u003e\n\u003cul class=\"[li_\u0026amp;]:mb-0 [li_\u0026amp;]:mt-1 [li_\u0026amp;]:gap-1 [\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3\"\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eSterility Testing\u003c\/strong\u003e — confirmed sterile, free from viable microorganisms\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003ePyrogen \/ Endotoxin Testing\u003c\/strong\u003e — confirmed pyrogen-free by LAL (Limulus Amebocyte Lysate) assay\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eBenzyl Alcohol Content\u003c\/strong\u003e — verified at 0.9% (9 mg\/mL) by validated assay\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003epH Verification\u003c\/strong\u003e — confirmed within the 4.5–7.0 range\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eParticulate Matter Testing\u003c\/strong\u003e — confirmed free from visible particulates\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eCertificate of Analysis (CoA)\u003c\/strong\u003e — available upon request\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eEssential Accessory for Every Peptide Researcher\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eBAC water is a consumable that every serious research peptide laboratory requires. We recommend maintaining an adequate supply to support your full research protocol — running out mid-study and substituting an alternative reconstitution vehicle can introduce a variable that undermines experimental comparability. Given the investment represented by high-purity research peptides, using a matched, research-grade reconstitution solution is a straightforward way to protect that investment and maintain the integrity of your experimental data.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eIf you are purchasing any lyophilised peptide from our catalogue — whether BPC-157, TB-500, GHK-Cu, MOTS-c, Selank, tesamorelin, HGH, retatrutide, or any other compound — we recommend including bacteriostatic water in your order.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003eImportant Notice\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003eThis product is intended strictly for research and laboratory use only. Bacteriostatic water containing benzyl alcohol is not approved for use in neonates or premature infants, in whom benzyl alcohol toxicity has been documented at high doses. This product must not be self-administered or used outside of appropriately supervised research or clinical contexts. By purchasing this product, the buyer confirms they are a qualified researcher and will use it solely for lawful scientific research purposes.\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e","brand":"NEXYRALAB","offers":[{"title":"10ml","offer_id":59643105149262,"sku":null,"price":7.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1035\/3351\/0990\/files\/hf_20260512_165507_cb36c0a9-b827-4e01-bba7-05b9129f574b.png?v=1779451016"},{"product_id":"cjc-1295-no-dac","title":"CJC-1295 No DAC","description":"\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eCJC-1295 No DAC | Modified GRF (1-29) | Tetrasubstituted GHRH Analogue | Research Peptide\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eAlso Known As:\u003c\/strong\u003e Modified GRF (1-29), Mod GRF 1-29, CJC-1295 without DAC, tetrasubstituted GRF (1-29) \u003cstrong\u003eSequence:\u003c\/strong\u003e Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂ \u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C₁₅₂H₂₅₂N₄₄O₄₂ \u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 3367.97 g\/mol \u003cstrong\u003eKey Substitutions:\u003c\/strong\u003e D-Ala² | Gln⁸ | Ala¹⁵ | Leu²⁷ (tetrasubstituted) \u003cstrong\u003ePurity:\u003c\/strong\u003e \u0026gt;99% (HPLC verified) \u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder \u003cstrong\u003eAvailable Sizes:\u003c\/strong\u003e 5mg | 10mg \u003cstrong\u003eStorage:\u003c\/strong\u003e –20°C, away from light and moisture \u003cstrong\u003eCAS Number:\u003c\/strong\u003e 863288-34-0\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eWhat Is CJC-1295 No DAC?\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eCJC-1295 No DAC — formally known as Modified GRF (1-29), and sometimes abbreviated Mod GRF 1-29 — is a synthetic 29-amino acid analogue of endogenous growth hormone-releasing hormone (GHRH), engineered to deliver enhanced metabolic stability and sustained GHRH receptor activity while preserving the physiologically important pulsatile pattern of growth hormone secretion.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eTo understand CJC-1295 No DAC, it helps to understand the problem it was designed to solve. Endogenous GHRH is a 44-amino acid hypothalamic peptide that triggers GH release from anterior pituitary somatotrophs. However, the native molecule is rapidly degraded in circulation — primarily by the serum enzyme dipeptidyl peptidase-4 (DPP-4), which cleaves at the Tyr-Ala bond at the N-terminus — resulting in a biological half-life of just two to seven minutes. This extreme brevity makes native GHRH largely impractical as a sustained research tool.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eThe first step toward a solution was GRF (1-29), also known as sermorelin — a truncated 29-amino acid fragment of GHRH that retains full receptor binding and biological activity, as the first 29 residues contain the complete pharmacophore for GHRH receptor activation. Modified GRF (1-29) — CJC-1295 No DAC — takes this a step further through four targeted amino acid substitutions at positions 2, 8, 15, and 27 of the GRF (1-29) sequence:\u003c\/p\u003e\n\u003cul class=\"[li_\u0026amp;]:mb-0 [li_\u0026amp;]:mt-1 [li_\u0026amp;]:gap-1 [\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3\"\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003ePosition 2:\u003c\/strong\u003e L-alanine → D-alanine — provides primary protection against DPP-4 enzymatic cleavage at the N-terminus\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003ePosition 8:\u003c\/strong\u003e Asparagine → Glutamine — reduces oxidative instability during manufacture and storage\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003ePosition 15:\u003c\/strong\u003e Glycine → Alanine — enhances structural rigidity and reduces conformational susceptibility to peptidase activity\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003ePosition 27:\u003c\/strong\u003e Methionine → Leucine — eliminates a methionine oxidation site, significantly improving chemical stability\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eThese four substitutions collectively elevate the half-life of Modified GRF (1-29) from the two-to-seven minute range of native GHRH to approximately 30 minutes — long enough to produce a meaningful GH secretory pulse while remaining short enough to preserve the physiologically important pulsatile pattern of GH release and maintain hypothalamic-pituitary feedback regulation.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eA critical nomenclature note for researchers:\u003c\/strong\u003e The term \"CJC-1295\" in the scientific literature formally refers to CJC-1295 DAC — the albumin-binding, long-acting form of the compound developed by ConjuChem Biotechnologies, which carries an additional Drug Affinity Complex (DAC) modification enabling covalent binding to serum albumin and producing a half-life of approximately six to eight days. \"CJC-1295 No DAC\" or \"CJC-1295 without DAC\" is a widely used commercial synonym for Modified GRF (1-29) — and while this nomenclature is ubiquitous in the research peptide community, it is important for researchers to recognise that these are pharmacologically distinct compounds with substantially different pharmacokinetic profiles and experimental implications.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eOur CJC-1295 No DAC is synthesised under strict quality-controlled manufacturing conditions and verified to a purity of greater than 99% by HPLC and Mass Spectrometry. It is supplied as a lyophilised (freeze-dried) powder for maximum stability.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eResearch Background \u0026amp; Scientific Interest\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eCJC-1295 No DAC (Modified GRF 1-29) has been studied as a GHRH-axis research tool in the context of growth hormone secretion, GH\/IGF-1 axis biology, metabolic regulation, body composition, and somatopause research. Its primary scientific value lies in its ability to amplify physiological pulsatile GH secretion — making it a valuable tool for researchers seeking to study the effects of GHRH receptor activation and downstream GH\/IGF-1 signalling under conditions that preserve normal hormonal feedback architecture.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eGHRH Receptor Activation \u0026amp; Pulsatile GH Secretion\u003c\/strong\u003e CJC-1295 No DAC binds with high affinity to the GHRH receptor (GHRH-R) — a class B G protein-coupled receptor expressed on somatotroph cells of the anterior pituitary. Receptor binding activates the adenylate cyclase–cAMP–PKA intracellular signalling cascade, stimulating both acute GH secretion and GH gene transcription. Because the compound's half-life of approximately 30 minutes is short relative to the natural inter-pulse interval of GH secretion (typically 90–180 minutes), CJC-1295 No DAC produces discrete GH pulses that mimic the physiological secretory pattern rather than creating sustained GH elevation. This pulsatile character is considered experimentally important: the liver and peripheral tissues respond differently to pulsatile versus continuous GH exposure, and several of GH's anabolic and lipolytic effects are specifically dependent on the pulse pattern rather than mean concentration. Researchers studying the distinction between physiological and pharmacological GH signalling will find this a meaningful design consideration in protocol selection.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eCJC-1295 No DAC vs. Tesamorelin: Pharmacokinetic Research Design Considerations\u003c\/strong\u003e Both CJC-1295 No DAC and tesamorelin are stabilised GHRH analogues that act at the GHRH receptor to stimulate pulsatile GH secretion — and they are frequently compared by researchers selecting between them. The key differences are structural and pharmacokinetic. Tesamorelin is a 44-amino acid analogue of full-length GHRH, stabilised by an N-terminal trans-3-hexenoic acid modification and carrying a half-life of approximately 30–40 minutes. CJC-1295 No DAC is a tetrasubstituted 29-amino acid fragment with a half-life of approximately 30 minutes. Both produce physiologically comparable pulsatile GH release patterns and preserve feedback regulation. Tesamorelin carries the more extensive clinical validation dataset — including FDA approval and large Phase III trial data — while CJC-1295 No DAC is more widely used as a general-purpose GHRH-axis research tool given its broader availability and established use in the preclinical literature. Both are available in our catalogue, allowing researchers to select the most appropriate compound for their experimental model. Tesamorelin is generally preferred when clinical translatability or regulatory alignment is a research priority; CJC-1295 No DAC is appropriate for preclinical mechanistic studies of the GHRH-GH-IGF-1 axis.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eCJC-1295 No DAC vs. CJC-1295 DAC: Key Research Design Distinction\u003c\/strong\u003e The choice between CJC-1295 No DAC and CJC-1295 DAC is one of the most consequential protocol decisions in GHRH-axis research, yet it is frequently confused — including, as noted above, in some published scientific literature. CJC-1295 No DAC produces a ~30 minute half-life with discrete pulsatile GH secretion. CJC-1295 DAC — through its albumin-binding Drug Affinity Complex — achieves a half-life of approximately six to eight days, producing sustained GH elevation across a prolonged period and blunting the natural pulse architecture. These are fundamentally different experimental conditions. Researchers studying physiological GH pulsatility, natural feedback dynamics, or acute GHRH receptor pharmacology should use CJC-1295 No DAC. Researchers studying the effects of sustained GH elevation, or requiring a long-acting dosing interval, should use CJC-1295 DAC. Using the wrong compound for the experimental question is a meaningful source of variability and potential error in GH-axis research design.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eGH\/IGF-1 Axis \u0026amp; Anabolic Signalling Research\u003c\/strong\u003e As a GHRH receptor agonist, CJC-1295 No DAC elevates GH secretion, which in turn drives hepatic and peripheral IGF-1 production. IGF-1 — acting through the IGF-1 receptor and downstream PI3K–Akt–mTOR and MAPK signalling cascades — mediates the principal anabolic, growth-promoting, and tissue-remodelling effects of the GH\/IGF-1 axis. Preclinical research has examined CJC-1295 No DAC (and related GHRH analogues) in models of skeletal muscle protein synthesis, lean mass accretion, adipose tissue lipolysis, bone mineral density, and collagen synthesis — with IGF-1 elevation identified as the primary mediator of these downstream effects.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eMetabolic \u0026amp; Body Composition Research\u003c\/strong\u003e Growth hormone directly stimulates lipolysis in adipose tissue via hormone-sensitive lipase activation, and indirectly promotes lean mass accrual through IGF-1-mediated protein synthesis and nitrogen retention. CJC-1295 No DAC's amplification of pulsatile GH secretion has made it a useful tool in preclinical studies examining these metabolic effects, including models of age-related body composition change and GH deficiency states. The compound's preservation of pulsatile GH dynamics is particularly relevant in this context, as the lipolytic effects of GH are known to be pulse-amplitude-dependent.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eSomatopause \u0026amp; Ageing Research\u003c\/strong\u003e The progressive decline in GHRH output and GH pulsatility with age — somatopause — produces a characteristic pattern of metabolic deterioration including increased visceral adiposity, reduced lean mass, and impaired tissue repair capacity. CJC-1295 No DAC, as a tool for restoring GHRH receptor stimulation and augmenting pulsatile GH output, has been studied in preclinical models of somatopause-associated metabolic change. Its mechanism of action — upstream stimulation of pituitary GH secretion rather than exogenous GH replacement — preserves the regulatory architecture of the hypothalamic-pituitary axis, making it a pharmacologically distinct tool from direct rhGH administration in ageing research models.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eCombination Research with GHRPs\u003c\/strong\u003e CJC-1295 No DAC is frequently studied in combination with growth hormone-releasing peptides (GHRPs) — including ipamorelin, GHRP-2, and GHRP-6 — in preclinical research protocols. GHRPs act at the ghrelin receptor (GHSR-1a) to amplify GH secretion through a distinct and mechanistically complementary pathway from GHRH receptor activation. The combination of a GHRH analogue (CJC-1295 No DAC) with a GHRP is known to produce synergistic GH release substantially exceeding the effect of either compound alone — a finding consistent with the known synergistic relationship between the GHRH and ghrelin pathways in regulating pituitary GH secretion. This combination approach has become one of the most common experimental paradigms in preclinical GH-axis research and is an important consideration for researchers designing multi-peptide studies.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eProduct Specifications\u003c\/h3\u003e\n\u003cdiv class=\"overflow-x-auto w-full px-2 mb-6\"\u003e\n\u003ctable class=\"min-w-full border-collapse text-sm leading-[1.7] whitespace-normal\"\u003e\n\u003cthead class=\"text-left\"\u003e\n\u003ctr\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eSpecification\u003c\/th\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eDetail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePeptide\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eCJC-1295 No DAC (Modified GRF 1-29)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eAlso Known As\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eMod GRF 1-29, Modified GRF (1-29), CJC-1295 without DAC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSequence\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eTyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eKey Substitutions\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eD-Ala² \/ Gln⁸ \/ Ala¹⁵ \/ Leu²⁷\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eMolecular Formula\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eC₁₅₂H₂₅₂N₄₄O₄₂\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eMolecular Weight\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e3367.97 g\/mol\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePurity\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e\u0026gt;99% (HPLC \u0026amp; MS verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eForm\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eLyophilised powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eVial Sizes\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e5mg, 10mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eAppearance\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eWhite to off-white powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSolubility\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSoluble in sterile bacteriostatic water or PBS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eApproximate Half-Life\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e~30 minutes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eStorage\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e–20°C, keep away from light\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eShelf Life\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e24 months when stored correctly (lyophilised)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eCAS Number\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e863288-34-0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eQuality \u0026amp; Purity Assurance\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eEvery batch of our CJC-1295 No DAC undergoes a rigorous multi-stage quality control process before release. Our assurance pipeline includes:\u003c\/p\u003e\n\u003cul class=\"[li_\u0026amp;]:mb-0 [li_\u0026amp;]:mt-1 [li_\u0026amp;]:gap-1 [\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3\"\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eHPLC Analysis\u003c\/strong\u003e — confirms peptide purity exceeding 99%\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eMass Spectrometry (MS)\u003c\/strong\u003e — verifies molecular identity, correct tetrasubstitution pattern, and full 29-residue sequence accuracy\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eEndotoxin Testing\u003c\/strong\u003e — ensures the product is free from bacterial endotoxins\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eCertificate of Analysis (CoA)\u003c\/strong\u003e — available for every batch upon request\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eFull batch traceability is maintained across synthesis, purification, and quality testing. The four amino acid substitutions are analytically critical features of Modified GRF (1-29) — our MS verification process explicitly confirms the correct substitution pattern to distinguish it from native GRF (1-29) or sermorelin, and to ensure research-grade accuracy.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eHandling \u0026amp; Reconstitution (Research Use)\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eCJC-1295 No DAC lyophilised powder should be reconstituted using sterile bacteriostatic water. Inject the water slowly against the side of the vial — not directly onto the powder — and swirl gently until fully dissolved. Do not vortex. Once reconstituted, aliquot and store at 2–8°C. Use within 28–30 days of reconstitution. Avoid repeated freeze-thaw cycles to preserve peptide integrity.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eAll handling should comply with standard laboratory safety protocols and applicable institutional or regulatory guidelines.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eCJC-1295 No DAC Within the Research Peptide Catalogue\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eCJC-1295 No DAC occupies the GHRH secretagogue position within our GH-axis research toolkit. Together with tesamorelin (a 44-residue GHRH analogue with FDA validation) and recombinant human growth hormone (rhGH, the direct GH replacement standard), it provides researchers with three mechanistically distinct points of entry into GH\/IGF-1 axis research: upstream GHRH stimulation with pulsatile GH output (CJC-1295 No DAC and tesamorelin), and direct exogenous GH replacement (rhGH).\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eWithin the broader catalogue, CJC-1295 No DAC's GH\/IGF-1 axis effects are mechanistically distinct from — and complementary to — the tissue-repair focus of BPC-157 and TB-500, the dermal and genomic biology of GHK-Cu, the mitochondrial metabolic signalling of MOTS-c, the systemic hormonal triple agonism of retatrutide, the intracellular NAD+ axis of 5-Amino-1MQ, and the neuropeptide biology of Selank. Together, these compounds represent a catalogue spanning the most actively researched peptide mechanisms in contemporary preclinical science.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eAll peptides are manufactured to the same \u0026gt;99% purity standard and supported by batch-specific Certificates of Analysis.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003eImportant Notice\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003eThis product is intended strictly for in vitro research and laboratory use only. CJC-1295 No DAC (Modified GRF 1-29) is not approved for human or veterinary use by the FDA, EMA, or any other regulatory authority. It is not a drug, supplement, or food product. This product must not be administered to humans or animals. By purchasing this product, the buyer confirms they are a qualified researcher and will use the compound solely for lawful scientific research purposes.\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e","brand":"NEXYRALAB","offers":[{"title":"5mg","offer_id":59643105345870,"sku":null,"price":19.99,"currency_code":"GBP","in_stock":true},{"title":"10mg","offer_id":59643105378638,"sku":null,"price":33.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1035\/3351\/0990\/files\/hf_20260512_163446_a184d5f4-c05e-4c18-ba23-8e33786e14a6.png?v=1779451021"},{"product_id":"ipamorelin","title":"Ipamorelin","description":"\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eIpamorelin | Aib-His-D-2-Nal-D-Phe-Lys-NH₂ | Selective GHS-R1a Agonist | Research Peptide\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e Aib-His-D-2-Nal-D-Phe-Lys-NH₂ \u003cstrong\u003eClassification:\u003c\/strong\u003e Synthetic pentapeptide — selective growth hormone secretagogue receptor 1a (GHS-R1a) agonist \/ GHRP \u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C₃₈H₄₉N₉O₅ \u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 711.85 g\/mol \u003cstrong\u003eKey Structural Features:\u003c\/strong\u003e α-aminoisobutyric acid (Aib) at position 1; D-2-naphthylalanine (D-2-Nal) at position 3; D-phenylalanine (D-Phe) at position 4 \u003cstrong\u003ePurity:\u003c\/strong\u003e \u0026gt;99% (HPLC verified) \u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder \u003cstrong\u003eAvailable Sizes:\u003c\/strong\u003e 5mg | 10mg \u003cstrong\u003eStorage:\u003c\/strong\u003e –20°C, away from light and moisture \u003cstrong\u003eCAS Number:\u003c\/strong\u003e 170851-70-4\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eWhat Is Ipamorelin?\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eIpamorelin is a synthetic pentapeptide growth hormone-releasing peptide (GHRP) and selective agonist of the ghrelin receptor (GHS-R1a), originally developed by Novo Nordisk in Denmark and first characterised in a landmark 1998 paper in the European Journal of Endocrinology by Raun and colleagues. It was derived from GHRP-1 through a systematic chemistry programme that identified active analogues lacking the central Ala-Trp dipeptide of the parent compound, ultimately yielding ipamorelin as the most pharmacologically refined member of its series.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eIpamorelin's significance in the research peptide landscape rests on a single, defining characteristic: it is the first growth hormone-releasing peptide receptor agonist to demonstrate a selectivity for GH release comparable to that of endogenous GHRH itself. All earlier GHRPs — including GHRP-2 and GHRP-6 — stimulated GH release but also produced dose-dependent elevations in ACTH and cortisol through activation of broader stress-response signalling pathways. Ipamorelin does not. In the foundational Novo Nordisk pharmacology studies, ipamorelin failed to elevate ACTH or cortisol at doses more than 200-fold above its ED50 for GH release — a specificity profile that had not previously been achieved with any GHRP receptor agonist and that fundamentally changed the landscape of GH secretagogue research.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eStructurally, ipamorelin incorporates three key non-natural amino acid features that underpin its selectivity and metabolic stability. The α-aminoisobutyric acid (Aib) residue at position 1 confers resistance to N-terminal peptidase cleavage. The D-2-naphthylalanine (D-2-Nal) at position 3 — a bulky, non-natural amino acid — provides critical receptor binding contributions and contributes to selectivity. The D-phenylalanine (D-Phe) at position 4 further stabilises the receptor-bound conformation. Together, these modifications produce a compound with substantially lower systemic plasma clearance than GHRP-6 — approximately five-fold lower — and moderate resistance to metabolic degradation, resulting in a more sustained and reproducible GH secretory response.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eIpamorelin stimulates pulsatile GH secretion from anterior pituitary somatotrophs by acting at the ghrelin receptor (GHS-R1a) — a distinct and mechanistically complementary pathway to the GHRH receptor pathway through which CJC-1295 No DAC and tesamorelin operate. This mechanistic distinction is the basis of the well-established synergistic relationship between ipamorelin and GHRH analogues in GH secretion research.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eOur ipamorelin is synthesised under rigorous quality-controlled manufacturing conditions, verified to a purity of greater than 99% by HPLC and Mass Spectrometry, and supplied as a lyophilised (freeze-dried) powder for maximum stability.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eResearch Background \u0026amp; Scientific Interest\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eIpamorelin has accumulated a rich and diverse body of preclinical research since its characterisation in 1998, spanning GH secretagogue pharmacology, metabolic biology, bone mineral density, gastrointestinal motility, and body composition research. Its defining selectivity profile has made it the reference compound of choice for ghrelin receptor agonism research where hormonal specificity is a priority experimental requirement.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eGHS-R1a Receptor Pharmacology \u0026amp; Selectivity\u003c\/strong\u003e Ipamorelin's receptor pharmacology was comprehensively characterised in the original Novo Nordisk studies. In vitro, ipamorelin released GH from primary rat pituitary cells with a potency and efficacy closely comparable to GHRP-6 — achieving an EC50 of 1.3 ± 0.4 nmol\/L and an Emax of 85 ± 5% relative to GHRP-6's 100% reference maximum. In vivo, in conscious swine — a model with GH axis pharmacology closely reflective of human GH secretion — ipamorelin produced an ED50 of 2.3 ± 0.03 nmol\/kg and an Emax of 65 ± 0.2 ng GH\/mL plasma, comparable to GHRP-6 (ED50 3.9 ± 1.4 nmol\/kg, Emax 74 ± 7 ng\/mL) but with substantially superior selectivity. Critically, pharmacological profiling using both GHRP receptor antagonists and GHRH antagonists confirmed that ipamorelin stimulates GH release exclusively via the GHRP\/ghrelin receptor pathway — the same receptor used by GHRP-2 and GHRP-6 — rather than through the GHRH receptor. This orthogonal mechanism is the mechanistic basis of the synergistic GH release observed when ipamorelin is combined with GHRH analogues such as CJC-1295 No DAC.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eHormonal Selectivity: No ACTH, Cortisol, Prolactin or Gonadotropin Elevation\u003c\/strong\u003e The most scientifically significant finding in the ipamorelin pharmacology literature is its hormonal selectivity profile. In the definitive swine selectivity study, none of the GH secretagogues tested — including ipamorelin, GHRP-6, and GHRP-2 — affected FSH, LH, prolactin, or TSH levels. However, administration of both GHRP-6 and GHRP-2 produced significant elevations in plasma ACTH and cortisol. Ipamorelin produced no significant elevation in ACTH or cortisol at any dose tested — including doses exceeding 200-fold the GH-releasing ED50. This was described by the original authors as \"very surprising\" and represented a categorically different selectivity profile from all previously characterised GHRP receptor agonists. The practical research implication is substantial: studies using ipamorelin to investigate GH\/IGF-1 axis effects are not confounded by concurrent activation of the hypothalamic-pituitary-adrenal (HPA) axis — a major experimental advantage over GHRP-2 and GHRP-6 in any protocol where cortisol or ACTH are outcome variables, or where HPA axis activation would represent an uncontrolled experimental variable.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003ePulsatile GH Secretion \u0026amp; IGF-1 Axis Research\u003c\/strong\u003e Like CJC-1295 No DAC, ipamorelin stimulates pulsatile rather than continuous GH secretion. Its half-life of approximately two hours in rodent models — longer than GHRP-6 due to its approximately five-fold lower systemic plasma clearance — produces GH pulses of meaningful duration while preserving the inter-pulse intervals that allow natural somatostatin feedback to operate. Elevated GH secretion drives downstream IGF-1 production, mediated primarily through hepatic GH receptor signalling, and the GH\/IGF-1 axis effects of ipamorelin — including anabolic signalling in skeletal muscle, lipolytic activity in adipose tissue, and effects on bone metabolism — have been studied in multiple preclinical models.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eBone Mineral Density Research\u003c\/strong\u003e Ipamorelin has been studied in models of bone metabolism, with preclinical data demonstrating increases in bone mineral content (BMC) in treated female rats as measured by dual-energy X-ray absorptiometry (DXA) in vivo. Comparative studies examining ipamorelin and GHRP-6 both demonstrated BMC increases, consistent with the known role of the GH\/IGF-1 axis in bone formation, periosteal expansion, and endochondral ossification. These findings have positioned ipamorelin as a tool of interest in preclinical osteoporosis research and models of GH deficiency-associated bone loss.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eGastrointestinal Motility Research\u003c\/strong\u003e The GHS-R1a receptor is expressed not only in the pituitary and hypothalamus but throughout the gastrointestinal tract — reflecting the physiological role of ghrelin as a gut-derived hormone regulating gastric motility and appetite. Ipamorelin has been studied in preclinical models of gastrointestinal dysfunction, including postoperative ileus (POI) — a clinically important condition characterised by delayed gastric emptying following abdominal surgery. Studies by Greenwood-Van Meerveld and colleagues using rodent POI models demonstrated that ipamorelin produced dose-dependent improvements in gastric emptying and reversal of POI-induced delayed gastrointestinal transit, with effects mediated through GHS-R1a expressed in gastrointestinal smooth muscle and enteric nervous system tissue. These findings have expanded ipamorelin's research relevance into gastrointestinal biology beyond its primary GH secretagogue profile.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eBody Composition \u0026amp; Metabolic Research\u003c\/strong\u003e The downstream metabolic effects of ipamorelin-stimulated GH\/IGF-1 axis activation — including GH-mediated lipolysis in adipose tissue, IGF-1-mediated skeletal muscle protein synthesis, and nitrogen retention — have made ipamorelin a useful tool in preclinical body composition research. Studies have examined ipamorelin in models of lean mass accretion, visceral fat reduction, and metabolic syndrome, with findings consistent with the broader GH\/IGF-1 axis literature. Its hormonal selectivity — specifically the absence of cortisol elevation — is a meaningful research advantage in these models, as elevated cortisol has well-documented catabolic effects on muscle tissue that would otherwise confound body composition outcomes.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eCombination Research: Ipamorelin + CJC-1295 No DAC (GHRH + GHRP Synergy)\u003c\/strong\u003e One of the most important and widely replicated findings in GH secretagogue research is the synergistic relationship between GHRH-axis peptides and GHRP-class peptides in stimulating GH release. When a GHRH analogue (such as CJC-1295 No DAC) and a GHRP (such as ipamorelin) are administered together, the combined GH release substantially exceeds the sum of the individual responses — a finding consistent with the well-established physiological synergism between the hypothalamic GHRH and ghrelin systems. This occurs because the two compounds act through distinct and mechanistically independent receptors (GHRH-R and GHS-R1a respectively), and their downstream signalling cascades converge synergistically at the level of pituitary somatotroph GH secretion. This combination paradigm — CJC-1295 No DAC paired with ipamorelin — has become one of the most commonly used experimental protocols in preclinical GH-axis research, and both compounds are available in our catalogue to support this research design.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eIpamorelin vs. GHRP-2 and GHRP-6: Selectivity Comparison\u003c\/h3\u003e\n\u003cdiv class=\"overflow-x-auto w-full px-2 mb-6\"\u003e\n\u003ctable class=\"min-w-full border-collapse text-sm leading-[1.7] whitespace-normal\"\u003e\n\u003cthead class=\"text-left\"\u003e\n\u003ctr\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eParameter\u003c\/th\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eIpamorelin\u003c\/th\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eGHRP-6\u003c\/th\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eGHRP-2\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eGH release potency (swine)\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eED50 ~2.3 nmol\/kg\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eED50 ~3.9 nmol\/kg\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eED50 ~0.6 nmol\/kg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eGH release efficacy (swine)\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eEmax ~65 ng\/mL\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eEmax ~74 ng\/mL\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eEmax ~56 ng\/mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eACTH\/cortisol elevation\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eNone (even at 200× ED50)\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSignificant\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSignificant\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eProlactin\/gonadotropin effects\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eNone\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eNone\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eNone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePlasma clearance vs GHRP-6\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e~5× lower\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eReference\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eLower than GHRP-6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eAppetite \/ gastric effects\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eMild (GHS-R1a mediated)\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSignificant\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eModerate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eThis table illustrates why ipamorelin has become the preferred GHRP for researchers where hormonal specificity and clean pharmacology are experimental priorities — delivering comparable GH release potency to GHRP-6 while eliminating the ACTH and cortisol confounders that complicate interpretation of results with the older compounds.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eProduct Specifications\u003c\/h3\u003e\n\u003cdiv class=\"overflow-x-auto w-full px-2 mb-6\"\u003e\n\u003ctable class=\"min-w-full border-collapse text-sm leading-[1.7] whitespace-normal\"\u003e\n\u003cthead class=\"text-left\"\u003e\n\u003ctr\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eSpecification\u003c\/th\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eDetail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePeptide\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eIpamorelin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSequence\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eAib-His-D-2-Nal-D-Phe-Lys-NH₂\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eClassification\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSelective GHS-R1a agonist \/ GHRP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eMolecular Formula\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eC₃₈H₄₉N₉O₅\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eMolecular Weight\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e711.85 g\/mol\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePurity\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e\u0026gt;99% (HPLC \u0026amp; MS verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eForm\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eLyophilised powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eVial Sizes\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e5mg, 10mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eAppearance\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eWhite to off-white powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSolubility\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSoluble in sterile bacteriostatic water or PBS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eStorage\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e–20°C, keep away from light\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eShelf Life\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e24 months when stored correctly (lyophilised)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eCAS Number\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e170851-70-4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eQuality \u0026amp; Purity Assurance\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eEvery batch of our ipamorelin undergoes a comprehensive multi-stage quality control process before release. Our assurance pipeline includes:\u003c\/p\u003e\n\u003cul class=\"[li_\u0026amp;]:mb-0 [li_\u0026amp;]:mt-1 [li_\u0026amp;]:gap-1 [\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3\"\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eHPLC Analysis\u003c\/strong\u003e — confirms peptide purity exceeding 99%\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eMass Spectrometry (MS)\u003c\/strong\u003e — verifies molecular identity, non-natural amino acid incorporation (Aib, D-2-Nal, D-Phe), and full pentapeptide sequence accuracy\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eEndotoxin Testing\u003c\/strong\u003e — ensures the product is free from bacterial endotoxins\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eCertificate of Analysis (CoA)\u003c\/strong\u003e — available for every batch upon request\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eThe three non-natural amino acids in ipamorelin — Aib, D-2-Nal, and D-Phe — are analytically critical features that distinguish it from related GHRPs. Our MS verification process explicitly confirms their incorporation to ensure the correct compound is delivered with research-grade accuracy and batch-to-batch consistency.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eHandling \u0026amp; Reconstitution (Research Use)\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eIpamorelin lyophilised powder should be reconstituted using sterile bacteriostatic water. Inject slowly against the side of the vial and swirl gently — do not vortex. Once reconstituted, aliquot and store at 2–8°C. Use within 28–30 days of reconstitution. The compound exhibits moderate resistance to metabolic degradation in solution, but repeated freeze-thaw cycles should nonetheless be avoided to maintain research-grade integrity.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eAll handling should comply with standard laboratory safety protocols and applicable institutional or regulatory guidelines.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eIpamorelin Within the Research Peptide Catalogue\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eIpamorelin occupies the ghrelin receptor agonist \/ GHRP position within our GH-axis research toolkit — mechanistically complementary to, and synergistic with, the GHRH-axis compounds CJC-1295 No DAC and tesamorelin, and distinct from the direct GH replacement approach of rhGH.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eWithin the broader catalogue, ipamorelin's GHS-R1a-mediated GH\/IGF-1 axis activity is mechanistically distinct from the tissue-repair focus of BPC-157 and TB-500, the genomic and matrix biology of GHK-Cu, the mitochondrial metabolic signalling of MOTS-c, the systemic triple hormonal agonism of retatrutide, the intracellular NAD+ axis of 5-Amino-1MQ, and the neuropeptide biology of Selank. Our full GH axis research toolkit now comprises three distinct mechanistic entry points: ghrelin receptor agonism (ipamorelin), GHRH receptor agonism (CJC-1295 No DAC, tesamorelin), and direct GH replacement (rhGH) — providing researchers with the tools to study GH biology from upstream secretagogue stimulation through to receptor-level replacement.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eAll peptides are manufactured to the same \u0026gt;99% purity standard and supported by batch-specific Certificates of Analysis.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003eImportant Notice\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003eThis product is intended strictly for in vitro research and laboratory use only. Ipamorelin is not approved for human or veterinary use by the FDA, EMA, or any other regulatory authority. It is not a drug, supplement, or food product. This product must not be administered to humans or animals. By purchasing this product, the buyer confirms they are a qualified researcher and will use the compound solely for lawful scientific research purposes.\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e","brand":"NEXYRALAB","offers":[{"title":"5mg","offer_id":59643105542478,"sku":null,"price":15.99,"currency_code":"GBP","in_stock":true},{"title":"10mg","offer_id":59643105575246,"sku":null,"price":29.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1035\/3351\/0990\/files\/hf_20260512_161949_79447409-1a83-4bd4-8386-ce029588bbff.png?v=1779451031"},{"product_id":"tesamorelin-th9507","title":"Tesamorelin (TH9507) Peptide","description":"\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eTesamorelin | TH9507 | Stabilised Growth Hormone-Releasing Hormone Analogue | Research Peptide\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eAlso Known As:\u003c\/strong\u003e TH9507, Egrifta (pharmaceutical brand name) \u003cstrong\u003eSequence:\u003c\/strong\u003e Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu (44 residues, N-terminally modified) \u003cstrong\u003eModification:\u003c\/strong\u003e Trans-3-hexenoic acid moiety conjugated to N-terminal tyrosine residue \u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C₂₂₁H₃₆₆N₇₂O₆₇S \u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 5135.77 g\/mol \u003cstrong\u003ePurity:\u003c\/strong\u003e \u0026gt;99% (HPLC verified) \u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder \u003cstrong\u003eAvailable Sizes:\u003c\/strong\u003e 5mg | 10mg \u003cstrong\u003eStorage:\u003c\/strong\u003e 2–8°C (refrigerated); –20°C for long-term storage \u003cstrong\u003eCAS Number:\u003c\/strong\u003e 218949-48-5\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eWhat Is Tesamorelin?\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eTesamorelin (developmental code: TH9507; brand name Egrifta) is a synthetic 44-amino acid analogue of endogenous human growth hormone-releasing hormone (GHRH), developed by Theratechnologies Inc. and approved by the U.S. Food and Drug Administration (FDA) in 2010 — making it one of the very few research-grade peptides with full FDA approval and an extensive human clinical trial dataset behind it.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eEndogenous GHRH is a 44-amino acid hypothalamic peptide that binds to GHRH receptors on somatotroph cells in the anterior pituitary, stimulating the synthesis and pulsatile secretion of growth hormone (GH). While native GHRH is pharmacologically active, it is rapidly degraded in vivo by the serum enzyme dipeptidyl peptidase-4 (DPP-4) — which cleaves at the Tyr-Ala bond at the N-terminus — resulting in a biological half-life of only a few minutes and rendering it largely unsuitable as a sustained research tool.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eTesamorelin addresses this limitation through a precise structural modification: conjugation of a trans-3-hexenoic acid moiety to the N-terminal tyrosine residue. This hydrophobic modification sterically protects the DPP-4 cleavage site, producing a compound with significantly enhanced metabolic stability while retaining full agonist activity at the GHRH receptor. The result is a peptide that reproduces the physiological pulsatile pattern of GH secretion — preserving the natural hypothalamic-pituitary feedback architecture — rather than delivering continuous, supraphysiological GH exposure as exogenous rhGH administration does. This key distinction has major implications for research design and for the safety and hormonal specificity profile of tesamorelin relative to direct GH administration.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eOur tesamorelin is synthesised under strict quality-controlled manufacturing conditions, verified to a purity of greater than 99% by High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS), and supplied as a lyophilised (freeze-dried) powder for optimal stability.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eResearch Background \u0026amp; Clinical Data\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eTesamorelin carries one of the most extensive and rigorously validated clinical research profiles of any peptide available for laboratory study. It has been evaluated in large-scale, randomised, double-blind, placebo-controlled Phase III trials involving over 800 participants, with findings published in leading peer-reviewed journals. This level of clinical evidence is exceptional within the research peptide landscape and makes tesamorelin a uniquely robust reference compound for the GH\/IGF-1 axis.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eMechanism: GHRH Receptor Activation \u0026amp; Pulsatile GH Secretion\u003c\/strong\u003e Tesamorelin binds with high affinity to the growth hormone-releasing hormone receptor (GHRH-R) — a G-protein-coupled receptor expressed predominantly on somatotroph cells of the anterior pituitary. Receptor binding activates the adenylate cyclase–cAMP–PKA intracellular signalling cascade, promoting both acute GH release and longer-term GH gene transcription. Critically, this mechanism preserves the natural pulsatile pattern of GH secretion and maintains hypothalamic-pituitary IGF-1 feedback inhibition — meaning GH release remains physiologically regulated rather than driven to sustained supraphysiological levels. Downstream, elevated GH stimulates hepatic and peripheral production of IGF-1 and IGF binding protein-3 (IGFBP-3), which mediate the compound's anabolic, lipolytic, and tissue-remodelling effects at target tissues.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003ePulsatile GH Augmentation — Clinical Study in Healthy Males\u003c\/strong\u003e A landmark mechanistic study published in the Journal of Clinical Endocrinology \u0026amp; Metabolism examined the effects of tesamorelin at 2 mg daily for two weeks in 13 healthy males. Tesamorelin significantly increased mean overnight GH, average GH peak area, and basal GH secretion. IGF-1 increased by 181 ± 22 μg\/litre (P \u0026lt; 0.0001), while neither fasting glucose nor insulin-stimulated glucose uptake was significantly affected — an important finding demonstrating that tesamorelin's GH stimulation can substantially elevate IGF-1 without impairing peripheral insulin sensitivity, a key differentiator from direct exogenous rhGH administration.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003ePhase III Clinical Trials: HIV-Associated Lipodystrophy (LIPO-010 \u0026amp; CTR-1011)\u003c\/strong\u003e The pivotal Phase III evidence base for tesamorelin comprises two large, multicentre, randomised, double-blind, placebo-controlled trials — LIPO-010 (n=412) and CTR-1011 (n=404) — enrolling a combined total of 816 HIV-infected patients with excess visceral adiposity associated with antiretroviral therapy. Across both trials, tesamorelin demonstrated consistent reductions in visceral adipose tissue (VAT) of approximately 15–20%, accompanied by improvements in triglycerides, waist circumference, and patient-reported body image outcomes. These results were robust, reproducible across both trials, and formed the basis of the compound's FDA approval in 2010 as the first and only medication specifically indicated for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. An important finding from these trials was that tesamorelin significantly reduced visceral adipose tissue without adversely affecting subcutaneous fat or inducing insulin resistance — a clinically meaningful distinction from direct GH therapy.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eNAFLD \u0026amp; Liver Fat Research — The Lancet HIV\u003c\/strong\u003e Beyond visceral fat reduction, tesamorelin has been studied in models of metabolic dysfunction-associated liver disease. Tesamorelin is also being evaluated as therapy for insulin resistance, obesity, and nonalcoholic fatty liver disease. In a substudy examining HIV-positive participants with NAFLD, tesamorelin produced clinically meaningful reductions in liver fat content and, in some analyses, attenuation of fibrosis progression markers — findings of significant interest to researchers working in hepatology and liver metabolic disease.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eCardiovascular Research\u003c\/strong\u003e In a study of tesamorelin (2 mg\/day subcutaneously) in 60 abdominally obese volunteers with reduced peak GH stimulation, 12 months of treatment significantly decreased carotid intima-media thickness (cIMT), VAT, C-reactive protein, and triglycerides compared to placebo. Reductions in cIMT — a validated surrogate marker of coronary atherosclerosis — are of particular interest to cardiovascular researchers, though the relative contributions of IGF-1 elevation, VAT reduction, and anti-inflammatory effects to this outcome continue to be investigated.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eCognitive \u0026amp; Neuroendocrine Research\u003c\/strong\u003e An emerging and scientifically compelling area of tesamorelin research concerns cognitive function and neuroendocrine biology. Given the well-established role of the GH\/IGF-1 axis in hippocampal neurogenesis, synaptic plasticity, and neuroprotection — and the progressive decline of GH secretion with age — tesamorelin has been investigated as a research tool for examining GH-mediated cognitive effects. Studies have explored tesamorelin's influence on verbal memory, executive function, and brain amyloid-beta metabolism in older adults, with findings suggesting a potential role for the GH\/IGF-1 axis in age-related cognitive trajectories that merits continued investigation.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eMetabolic Syndrome \u0026amp; Insulin Resistance Research\u003c\/strong\u003e Beyond the HIV-lipodystrophy indication, researchers have studied tesamorelin in broader models of visceral obesity and metabolic syndrome. Tesamorelin's stimulation of pulsatile GH release is thought to preferentially target visceral adipose tissue, suppress hepatic lipogenesis, and improve body-composition biomarkers. Its selectivity for visceral over subcutaneous fat — a pattern consistent with the physiological role of pulsatile GH in fat distribution — makes tesamorelin a valuable tool for researchers seeking to dissect the specific metabolic consequences of visceral adiposity and GH axis dysregulation.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eAgeing \u0026amp; Somatopause Research\u003c\/strong\u003e The progressive decline in GH secretion with age — somatopause — is associated with increased visceral adiposity, reduced lean mass, impaired bone density, and deteriorating metabolic parameters. Tesamorelin's capacity to restore more youthful pulsatile GH dynamics without bypassing natural feedback mechanisms makes it an important research tool for studying somatopause-related metabolic changes and the role of the GH axis in healthy ageing trajectories. Unlike exogenous rhGH, which replaces GH directly and suppresses endogenous secretion, tesamorelin stimulates the pituitary — preserving the regulatory architecture while augmenting output.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eTesamorelin vs. Exogenous rhGH: A Key Research Distinction\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eA critical consideration for researchers choosing between tesamorelin and recombinant human growth hormone (rhGH) is the fundamentally different hormonal environment each creates. Direct rhGH administration delivers continuous, non-pulsatile GH exposure that can suppress endogenous GH secretion via negative feedback and frequently drives IGF-1 to supraphysiological levels — increasing the risk of insulin resistance and other GH excess effects. Tesamorelin, by contrast, stimulates the pituitary to release GH in the natural pulsatile pattern, maintains hypothalamic-pituitary feedback integrity, and produces more physiological IGF-1 elevation. This distinction is experimentally important: researchers studying the consequences of physiological versus supraphysiological GH axis activity, or seeking to model GH restoration without disrupting endocrine homeostasis, will find tesamorelin and rhGH produce meaningfully different experimental conditions that must be accounted for in protocol design.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eBoth tesamorelin and rhGH are available in our catalogue, allowing researchers to select the most appropriate tool for their specific experimental model.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eProduct Specifications\u003c\/h3\u003e\n\u003cdiv class=\"overflow-x-auto w-full px-2 mb-6\"\u003e\n\u003ctable class=\"min-w-full border-collapse text-sm leading-[1.7] whitespace-normal\"\u003e\n\u003cthead class=\"text-left\"\u003e\n\u003ctr\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eSpecification\u003c\/th\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eDetail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePeptide\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eTesamorelin (TH9507)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eClassification\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eStabilised GHRH analogue — 44-amino acid polypeptide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eN-terminal Modification\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eTrans-3-hexenoic acid (DPP-4 protection)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eMolecular Formula\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eC₂₂₁H₃₆₆N₇₂O₆₇S\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eMolecular Weight\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e5135.77 g\/mol\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePurity\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e\u0026gt;99% (HPLC \u0026amp; MS verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eForm\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eLyophilised powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eVial Sizes\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e5mg, 10mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eAppearance\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eWhite to off-white powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSolubility\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSoluble in sterile water or bacteriostatic water\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eStorage\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e2–8°C (short-term); –20°C (long-term, lyophilised)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eShelf Life\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e24 months lyophilised; use reconstituted solution within 28 days (2–8°C)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eCAS Number\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e218949-48-5\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eQuality \u0026amp; Purity Assurance\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eEvery batch of our tesamorelin undergoes a comprehensive multi-stage quality control process before release. Our assurance pipeline includes:\u003c\/p\u003e\n\u003cul class=\"[li_\u0026amp;]:mb-0 [li_\u0026amp;]:mt-1 [li_\u0026amp;]:gap-1 [\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3\"\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eHPLC Analysis\u003c\/strong\u003e — confirms peptide purity exceeding 99% and correct modification profile\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eMass Spectrometry (MS)\u003c\/strong\u003e — verifies molecular identity, N-terminal hexenoyl modification integrity, and full 44-residue sequence accuracy\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eSDS-PAGE\u003c\/strong\u003e — confirms correct molecular weight profile under denaturing conditions\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eEndotoxin Testing\u003c\/strong\u003e — ensures the product is free from bacterial endotoxins\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eCertificate of Analysis (CoA)\u003c\/strong\u003e — available for every batch upon request\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eFull batch traceability is maintained across synthesis, purification, and quality testing. The N-terminal modification is an analytically critical feature of tesamorelin that requires specific MS verification — our QC process explicitly confirms hexenoyl conjugation integrity to ensure research-grade reliability.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eHandling \u0026amp; Reconstitution (Research Use)\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eTesamorelin lyophilised powder should be reconstituted by gently adding sterile bacteriostatic water to the side of the vial — not directly onto the powder. Swirl gently until fully dissolved; do not vortex. Once reconstituted, aliquot immediately and store at 2–8°C for short-term use (within 28 days) or at –20°C in lyophilised form for long-term storage. Avoid repeated freeze-thaw cycles to preserve the integrity of the N-terminal modification and peptide structure.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eAs a larger modified peptide, tesamorelin shares some storage sensitivity characteristics with rhGH and should be handled with the same care given to other complex peptide research compounds. All handling should comply with standard laboratory safety protocols and applicable institutional or regulatory guidelines.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eTesamorelin Within the Research Peptide Catalogue\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eTesamorelin occupies a distinctive position within our catalogue as the only GHRH-axis upstream secretagogue — acting at the level of the hypothalamic-pituitary interface to stimulate endogenous GH production, rather than delivering GH directly as rhGH does. This upstream mechanism complements rhGH by allowing researchers to study pituitary-mediated GH secretion and the effects of physiological GH pulsatility, in contrast to the non-pulsatile exogenous GH exposure that rhGH produces.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eWithin the broader metabolic research landscape of the catalogue, tesamorelin's GH\/IGF-1 axis activity is mechanistically distinct from — and complementary to — the systemic triple hormone receptor agonism of retatrutide, the mitochondrial AMPK signalling of MOTS-c, and the intracellular NAD+ axis of 5-Amino-1MQ. Researchers studying visceral adiposity, metabolic ageing, or body composition from multiple mechanistic angles will find tesamorelin provides a physiological hormonal signalling perspective that is not replicated by any other compound in the catalogue.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eAll peptides in our catalogue are manufactured to the same \u0026gt;99% purity standard and are supported by batch-specific Certificates of Analysis.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003eImportant Notice\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003eThis product is intended strictly for in vitro research and laboratory use only. While tesamorelin (Egrifta) holds FDA approval for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, this research-grade product is not supplied for therapeutic use and must not be administered to humans or animals outside of appropriately authorised and supervised clinical contexts. It is not a supplement or food product. By purchasing this product, the buyer confirms they are a qualified researcher and will use the compound solely for lawful scientific research purposes.\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e","brand":"NEXYRALAB","offers":[{"title":"5mg","offer_id":59643106165070,"sku":null,"price":31.99,"currency_code":"GBP","in_stock":true},{"title":"10mg","offer_id":59643106197838,"sku":null,"price":58.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1035\/3351\/0990\/files\/hf_20260512_165945_694518ab-1023-49d6-a4fb-f65050e23721.png?v=1779451053"}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1035\/3351\/0990\/collections\/hf_20260512_192206_bc5e9668-dcad-4459-a062-a0585c5a37bd.png?v=1780245158","url":"https:\/\/nexyralab.com\/collections\/growth-hormone-secretagogues.oembed","provider":"Nexyralab.com","version":"1.0","type":"link"}